徳島大学 教育・研究者情報データベース(EDB)

1. (英) Kawano Tomoharu / (日) 河野 友晴

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 松久 宗英([徳島大学.先端酵素学研究所.基幹研究部門]/徳島大学病院アンチエイジングセンター センター長(併任))

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. 橋田 誠一([宮崎医科大学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Numata Satoshi / (日) 沼田 聡

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 藤本 一幸

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. 黒田 暁生([徳島大学.先端酵素学研究所.基幹研究部門])

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Yasuda Tetsuyuki / (日) 安田 哲行

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Miyashita Kazuyuki / (日) 宮下 和幸

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Sakamoto Fumie / (日) 坂本 扶美枝

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Katakami Naoto / (日) 片上 直人

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. (英) Matsuoka Taka-aki / (日) 松岡 孝昭

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus

(日) IA-2抗体の高感度検出法(ICT-EIA法)の開発と長期罹患若年性1型糖尿病患者における3種膵島関連自己抗体(GADA,IA-2A,IAA)の検出について

(英) <p>Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus Tomoharu Kawano, Satoshi Numata, Yuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda,Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-aki Matsuoka, Munehide Matsuhisa and Seiichi Hashida Summary Detection of pancreatic islet-related autoantibodies( insulin antibody [IAA]; glutamic acid decarboxylase antibody [GADA]; and islet antigen-2 antibody [IA-2A], is essential for the diagnosis and prediction of the onset of type I diabetes mellitus. Depending on the disease duration, the detection rate of each autoantibody is different, and using only one kind of autoantibody detection risks overlooking a positive result. The detection precision of type I diabetes mellitus would thus be improved by measuring all three kinds of autoantibodies. We developed a highly sensitive enzyme immunoassay( ICT-EIA) for IA-2 autoantibody. ICT-EIAs for IAA and GADA have already been developed. Using three ICT-EIAs, we attempted to measure autoantibodies in sera from patients with type I diabetes mellitus. Patients comprised 25 males and 51 females( mean age, 33.3±5.7 years; disease duration, 23.9±6.7 years) with type I diabetes mellitus who had been undergoing treatment with insulin for between 11 and 40 years. Among these patients, urinary C-peptide-positive results were seen in three patients. IAA, GADA and IA-2A in sera were measured by ICT-EIA. The newly developed ICT-EIA for IA-2 antibodies was approximately 100-times more sensitive than the conventional ELISA. The positive ratio was 77.6%, representing a high rate of detection. In addition, even in patients with a disease duration >30 years, the positive rate was 64.3%. ICT-EIA was thus suggested to be useful in combination assays for pancreatic islet-related autoantibodies (IAA, GADA and IA-2A).</p><p> </p><p></p>

(日) <p>Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus Tomoharu Kawano, Satoshi Numata, Yuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda,Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-aki Matsuoka, Munehide Matsuhisa and Seiichi Hashida Summary Detection of pancreatic islet-related autoantibodies( insulin antibody [IAA]; glutamic acid decarboxylase antibody [GADA]; and islet antigen-2 antibody [IA-2A], is essential for the diagnosis and prediction of the onset of type I diabetes mellitus. Depending on the disease duration, the detection rate of each autoantibody is different, and using only one kind of autoantibody detection risks overlooking a positive result. The detection precision of type I diabetes mellitus would thus be improved by measuring all three kinds of autoantibodies. We developed a highly sensitive enzyme immunoassay( ICT-EIA) for IA-2 autoantibody. ICT-EIAs for IAA and GADA have already been developed. Using three ICT-EIAs, we attempted to measure autoantibodies in sera from patients with type I diabetes mellitus. Patients comprised 25 males and 51 females( mean age, 33.3±5.7 years; disease duration, 23.9±6.7 years) with type I diabetes mellitus who had been undergoing treatment with insulin for between 11 and 40 years. Among these patients, urinary C-peptide-positive results were seen in three patients. IAA, GADA and IA-2A in sera were measured by ICT-EIA. The newly developed ICT-EIA for IA-2 antibodies was approximately 100-times more sensitive than the conventional ELISA. The positive ratio was 77.6%, representing a high rate of detection. In addition, even in patients with a disease duration >30 years, the positive rate was 64.3%. ICT-EIA was thus suggested to be useful in combination assays for pancreatic islet-related autoantibodies (IAA, GADA and IA-2A).</p><p> </p><p></p>